Relative Impact of Cytogenetic Abnormalities and Flow Cytometric Measurable Residual Disease on Outcome Following Allogeneic HCT for AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Haematologica
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia
Haematologica 2022 Aug 04;[EPub Ahead of Print], C Orvain, JA Wilson, M Fang, BM Sandmaier, E Rodríguez-Arbolí, BL Wood, M Othus, FR Appelbaum, RB WalterFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.